As a result, inhibition of GCPII was thought to be neuroprotective, and GCPII inhibitor administration increased brain NAAG levels, improving cognitive performance in mice with experimental autoimmune encephalomyelitis [9]. This evidence concerns the gene FOLH1 and experimental autoimmune encephalomyelitis.